Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting

American Heart Journal

Volumn 149, Issue 6, 2005, Pages 1135.e11-1135.e18

  De Luca, Leonardo ^a   De Persio, Giovanni ^a   Minati, Monia ^a   Iacoboni, Carlo ^a   Fedele, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PLACEBO; TICLOPIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; TIME SERIES ANALYSIS;

EID: 20544471424     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.02.015     Document Type: Article

References (44)

1. S.M. Haffner, S. Lehto, and T. Ronnemaa Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
2. Y. Cohen, I. Raz, and G. Merino Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium Am J Cardiol 81 1998 7 11
3. M.S. Gowda, J.L. Vacek, and D. Hallas One-year outcomes of diabetic versus nondiabetic patients with non-Q-wave acute myocardial infarction treated with percutaneous transluminal coronary angioplasty Am J Cardiol 81 1998 1067 1071
4. G.W. Barsness, E.D. Peterson, and E.M. Ohman Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty Circulation 96 1997 2551 2556
5. S.G. Ellis, and C.R. Narins Problem of angioplasty in diabetes Circulation 96 1997 1707 1710
6. B. Stein, W.S. Weintraub, and S.P. Gebhart Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty Circulation 91 1995 979 989
7. E. Alderman, M. Bourassa, and M.M. Brooks Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 96 1997 1761 1769
8. K.E. Kip, D.P. Faxon, and K.M. Detre Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry Circulation 94 1996 1818 1825
9. A. Kastrati, A. Schomig, and S. Elezi Predictive factors of restenosis after coronary stent placement J Am Coll Cardiol 30 1997 1428 1436
10. A.M. Lincoff Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial Am Heart J 139 2000 S46 S52
11. S.P. Marso, A.M. Lincoff, and S.G. Ellis Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic study Circulation 100 1999 2477 2784
12. M. Roffi, D.J. Moliterno, and B. Meier Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up Circulation 105 2002 2730 2736
13. R.A. Corpus, P.B. George, and J.A. House Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention J Am Coll Cardiol 43 2004 8 14
14. K. Iwakura, H. Ito, and M. Ikushima Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction J Am Coll Cardiol 41 2003 1 7
15. R.H. Cobin, J.A. Davidson, and O.P. Ganda American College of Endocrinology Consensus Statement on guidelines for glycemic control Endocr Pract 8 Suppl. 1 2002 5 11
16. S.G. Ellis, M.G. Vandormael, and M.J. Cowley Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection Circulation 82 1990 1193 1202
17. J.B. Muhlestein, J.L. Anderson, and B.D. Horne Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention Am Heart J 146 2003 351 358
18. M. Coutinho, H.C. Gerstein, and Y. Wang The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years Diabetes Care 22 1999 233 240
19. K.T. Khaw, N. Wareham, and R. Luben Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) BMJ 322 2001 15
20. J.I. Osende, J. Badimon, and V. Fuster Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control J Am Coll Cardiol 38 2001 1307 1312
21. D. Aronson, Z. Bloomgarden, and E.J. Rayfield Potential mechanisms promoting restenosis in diabetic patients J Am Coll Cardiol 27 1996 528 535
22. S.R. Wilson, B.A. Vakili, and W. Sherman Effect of diabetes on long-term mortality following contemporary percutaneous coronary intervention. Analysis of 4284 cases Diabetes Care 27 2004 1137 1142
23. E. Van Belle, R. Ketelers, and C. Bauters Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up. A key determinant of survival in diabetics after coronary balloon angioplasty Circulation 103 2001 1218 1224
24. R. Kornowski, and S. Fuchs Optimization of glycemic control and restenosis prevention in diabetic patients undergoing percutaneous coronary interventions J Am Coll Cardiol 43 2004 15 16
25. P. Mazeika, N. Prasad, and S. Bui Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus Am Heart J 145 2003 1013 1021
26. E. Van Belle, C. Bauters, and E. Hubert Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels Circulation 96 1997 1454 1460
27. S. Elezi, A. Kastrati, and J. Pache Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement J Am Coll Cardiol 32 1998 1866 1873
28. A. Abizaid, R. Kornowski, and G.S. Mintz The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation J Am Coll Cardiol 32 1998 584 589
29. S.P. Marso, K.H. Mak, and E.J. Topol Diabetes mellitus: biological determinants of atherosclerosis and restenosis Semin Interv Cardiol 4 1999 129 143
30. American Diabetes Association Clinical practice recommendations 2001 Diabetes Care 24 Suppl. 1 2001 S33 S43
31. S.B. King, and E. Mahmud Will blocking the platelet save the diabetic? Circulation 100 1999 2466 2468
32. H.K. Meier-Ewert, and R.W. Nesto Targeting the use of glycoprotein IIb/IIIa antagonists-the diabetic patient Rev Cardiovasc Med 3 2002 S20 S27
33. A.M. Lincoff Important triad in cardiovascular medicine. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade Circulation 107 2003 1556 1559
34. S.R. Steinhubl, K. Kottke-Marchant, and D.J. Moliterno Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention Circulation 100 1999 1977 1982
35. A.M. Lincoff, R.M. Califf, D.J. Moliterno For the Evaluation of Platelet IIb/IIIa Inhibition in Stenting investigators Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors N Engl J Med 341 1999 319 327
36. P. Theroux, J. Alexander, and C. Pharand Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction Circulation 102 2000 2466 2472
37. M. Roffi, D.P. Chew, and D. Mukherjee Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes Circulation 104 2001 2767 2771
38. D.L. Bhatt, S.P. Marso, and A.M. Lincoff Abciximab reduces mortality in diabetics following percutaneous coronary intervention J Am Coll Cardiol 35 2000 922 928
39. J. Mehilli, A. Kastrati, and H. Schühlen Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel Circulation 110 2004 3627 3635
40. D.L. Bhatt, S.P. Marso, and A.T. Hirsch Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus Am J Cardiol 90 2002 625 628
41. S.R. Mehta, S. Yusuf, and R.J. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
42. B. Jarvis, and K. Simpson Clopidogrel: a review of its use in the prevention of atherothrombosis Drugs 60 2000 347 377
43. I. Müller, M. Seyfarth, and S. Rüdiger Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement Heart 85 2001 92 93
44. A. Kastrati, J. Mehilli, and H. Schühlen A clinical trial of abciximab in elective percutaneous coronary inter-vention after pretreatment with clopidogrel N Engl J Med 350 2004 232 238